Diarylurea: A Privileged Scaffold in Drug Discovery and Therapeutic Development | Bentham Science
Login Register Cart 0
Generic placeholder image

Current Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 0929-8673
ISSN (Online): 1875-533X

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Editorial

Diarylurea: A Privileged Scaffold in Drug Discovery and Therapeutic Development

Author(s): Alessia Catalano*

Volume 29, Issue 25, 2022

Published on: 03 February, 2022

Page: [4302 - 4306] Pages: 5

DOI: 10.2174/0929867329666220111121251

Open Access Journals Promotions 2
« Previous Next »
[1]
Garuti, L.; Roberti, M.; Bottegoni, G.; Ferraro, M. Diaryl urea: A privileged structure in anticancer agents. Curr. Med. Chem., 2016, 23(15), 1528-1548.
[http://dx.doi.org/10.2174/0929867323666160411142532] [PMID: 27063259]
[2]
Catalano, A.; Iacopetta, D.; Sinicropi, M.S.; Franchini, C. Diarylureas as antitumor agents. Appl. Sci. (Basel), 2021, 11, 374.
[http://dx.doi.org/10.3390/app11010374] [PMID: 33477901]
[3]
Lin, Y.S.; Yang, H.; Ding, Y.; Cheng, Y.Z.; Shi, F.; Tan, J.; Deng, Z.Y.; Chen, Z.D.; Wang, R.F.; Ji, Q.H.; Huang, R.; Li, L.F. Do-nafenib in progressive locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer: Results of a randomized, multicenter phase II trial. Thyroid, 2021, 31(4), 607-615.
[http://dx.doi.org/10.1089/thy.2020.0235] [PMID: 32907500]
[4]
Yang, Y.; Zhu, H.; Li, Q. Partial response of donafenib as the third-line therapy in metastatic colon cancer: A case report. Medicine (Baltimore), 2021, 100(37), e27204.
[http://dx.doi.org/10.1097/MD.0000000000027204] [PMID: 34664852]
[5]
Keam, S.J.; Duggan, S. Donafenib: First approval. Drugs, 2021, 81(16), 1915-1920.
[http://dx.doi.org/10.1007/s40265-021-01603-0] [PMID: 34591285]
[6]
Rajendran, P.; Ben Ammar, R.; Al-Saeedi, F.J.; Elsayed Mohamed, M.; Islam, M.; Al-Ramadan, S.Y. Thidiazuron decreases epithelial-mesenchymal transition activity through the NF-kB and PI3K/AKT signalling pathways in breast cancer. J. Cell. Mol. Med., 2020, 24(24), 14525-14538.
[http://dx.doi.org/10.1111/jcmm.16079] [PMID: 33159487]
[7]
Blum, W.; Henzi, T.; Pecze, L.; Diep, K.L.; Bochet, C.G.; Schwaller, B. The phytohormone forchlorfenuron decreases viability and pro-liferation of malignant mesothelioma cells in vitro and in vivo. Oncotarget, 2019, 10(65), 6944-6956.
[http://dx.doi.org/10.18632/oncotarget.27341] [PMID: 31857849]
[8]
Dai, B.; Fan, M.; Yu, R.; Su, Q.; Wang, B.; Yang, T.; Liu, F.; Zhang, Y. Novel diphenyl urea derivative serves as an inhibitor on human lung cancer cell migration by disrupting EMT via Wnt/β-catenin and PI3K/Akt signaling. Toxicol. In Vitro, 2020, 69, 105000.
[http://dx.doi.org/10.1016/j.tiv.2020.105000] [PMID: 32942006]
[9]
Qi, B.; Zhang, R.; Sun, R.; Guo, M.; Zhang, M.; Wei, G.; Zhang, L.; Yu, S.; Huang, H. IGF-1R inhibitor PQ401 inhibits osteosarcoma cell proliferation, migration and colony formation. Int. J. Clin. Exp. Pathol., 2019, 12(5), 1589-1598.
[PMID: 31933976]
[10]
Faraji, A.; Oghabi Bakhshaiesh, T.; Hasanvand, Z.; Motahari, R.; Nazeri, E.; Boshagh, M.A.; Firoozpour, L.; Mehrabi, H.; Khalaj, A.; Esmaeili, R.; Foroumadi, A. Design, synthesis and evaluation of novel thienopyrimidine-based agents bearing diaryl urea functionality as potential inhibitors of angiogenesis. Eur. J. Med. Chem., 2021, 209, 112942.
[http://dx.doi.org/10.1016/j.ejmech.2020.112942] [PMID: 33328104]
[11]
Catalano, A.; Iacopetta, D.; Pellegrino, M.; Aquaro, S.; Franchini, C.; Sinicropi, M.S. Diarylureas: Repositioning from antitumor to antimicrobials or multi-target agents against new pandemics. Antibiotics (Basel), 2021, 10(1), 92.
[http://dx.doi.org/10.3390/antibiotics10010092] [PMID: 33477901]
[12]
Iacopetta, D.; Catalano, A.; Ceramella, J.; Saturnino, C.; Salvagno, L.; Ielo, I.; Drommi, D.; Scali, E.; Plutino, M.R.; Rosace, G.; Sinicropi, M.S. The different facets of triclocarban: A review. Molecules, 2021, 26(9), 2811.
[http://dx.doi.org/10.3390/molecules26092811] [PMID: 34068616]
[13]
Kim, S.A.; Rhee, M.S. Microbicidal effects of plain soap vs. triclocarban-based antibacterial soap. J. Hosp. Infect., 2016, 94(3), 276-280.
[http://dx.doi.org/10.1016/j.jhin.2016.07.010] [PMID: 27585555]
[14]
Pozzi, C.; Ferrari, S.; Cortesi, D.; Luciani, R.; Stroud, R.M.; Catalano, A.; Costi, M.P.; Mangani, S. The structure of Enterococcus fae-calis thymidylate synthase provides clues about folate bacterial metabolism. Acta Crystallogr. D Biol. Crystallogr., 2012, 68(Pt 9), 1232-1241.
[http://dx.doi.org/10.1107/S0907444912026236] [PMID: 22948925]
[15]
Catalano, A.; Iacopetta, D.; Rosato, A.; Salvagno, L.; Ceramella, J.; Longo, F.; Sinicropi, M.S.; Franchini, C. Searching for small mole-cules as antibacterials: Non-cytotoxic diarylureas analogues of triclocarban. Antibiotics (Basel), 2021, 10(2), 204.
[http://dx.doi.org/10.3390/antibiotics10020204] [PMID: 33669633]
[16]
Catalano, A.; Rosato, A.; Salvagno, L.; Iacopetta, D.; Ceramella, J.; Fracchiolla, G.; Sinicropi, M.S.; Franchini, C. Benzothiazole-containing analogues of triclocarban with potent antibacterial activity. Antibiotics (Basel), 2021, 10(7), 803.
[http://dx.doi.org/10.3390/antibiotics10070803] [PMID: 34356724]
[17]
Chang, H.C.; Huang, Y.T.; Chen, C.S.; Chen, Y.W.; Huang, Y.T.; Su, J.C.; Teng, L.J.; Shiau, C.W.; Chiu, H.C. In vitro and in vivo activity of a novel sorafenib derivative SC5005 against MRSA. J. Antimicrob. Chemother., 2016, 71(2), 449-459.
[http://dx.doi.org/10.1093/jac/dkv367] [PMID: 26553845]
[18]
Hroch, L.; Guest, P.; Benek, O.; Soukup, O.; Janockova, J.; Dolezal, R.; Kuca, K.; Aitken, L.; Smith, T.K.; Gunn-Moore, F.; Zala, D.; Ramsay, R.R.; Musilek, K. Synthesis and evaluation of frentizole-based indolyl thiourea analogues as MAO/ABAD inhibitors for Alz-heimer’s disease treatment. Bioorg. Med. Chem., 2017, 25(3), 1143-1152.
[http://dx.doi.org/10.1016/j.bmc.2016.12.029] [PMID: 28082069]
[19]
Azam, F.; Prasad, M.V.V.; Thangavel, N. Structure-based design, synthesis, and molecular modeling studies of 1-(benzo[d]thiazol-2-yl)-3-(substituted aryl) urea derivatives as novel anti-Parkinsonian agents. Med. Chem. Res., 2012, 21, 2630-2643.
[http://dx.doi.org/10.1007/s00044-011-9786-y]
[20]
Patterson, J.R.; Graves, A.P.; Stoy, P. Identification of diarylurea inhibitors of the cardiac-specific kinase TNNI3K by designing selec-tivity against VEGFR2, p38α and B-Raf. J. Med. Chem., 2021, 64(21), 15651-15670.
[http://dx.doi.org/10.1021/acs.jmedchem.1c00700]
[21]
Leas, D.A.; Sanford, A.G.; Wu, J.; Cal, M.; Kaiser, M.; Wittlin, S.; Hemsley, R.M.; Darner, E.B.; Lui, L.M.; Davis, P.H.; Vennerstrom, J.L. Diaryl ureas as an antiprotozoal chemotype. ACS Infect. Dis., 2021, 7(6), 1578-1583.
[http://dx.doi.org/10.1021/acsinfecdis.1c00135] [PMID: 33971090]
[22]
Catalano, A. COVID-19: Could irisin become the handyman myokine of the 21st century? Coronaviruses, 2020, 1, 32-41.
[http://dx.doi.org/10.2174/2666796701999200617154655]

Rights & Permissions Print Cite
Article Metrics
26
1
Wayfinder Image
Open Access Journals Promotions
World Antimicrobial Awareness Week
© 2024 Bentham Science Publishers | Privacy Policy